Renalytix Secures $4 Million in Financing

Renalytix plc (NASDAQ: RNLX) (LSE: RENX) has locked in a registered direct offering of ordinary shares with DB Capital Partners Healthcare, L.P. The offering, priced at $0.75 per NASDAQ ADS ($0.375 per common stock share), is expected to bring in up to $4 million in total financing. The funds will fuel commercial sales activity as the company navigates its Formal Sale Process. The deal includes an initial tranche of 2,666,667 Ordinary Shares, with an optional subsequent tranche at the discretion of the Purchaser. The completion of the offering is set for April 11, 2024, pending customary closing conditions. Renalytix's leadership in bioprognosis™ for kidney health positions it as a key player in the healthcare technology sector. For more information, visit www.renalytix.com.